44
Participants
Start Date
February 29, 2012
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
Laboratory Biomarker Analysis
Correlative studies
Linsitinib
150 mg given orally (PO) twice a day (BID)
Pharmacological Study
Correlative studies
Topotecan Hydrochloride
1.5 mg/m\^2 intravenously (IV) or 2.3 mg/m\^2 orally (PO)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore
Emory University/Winship Cancer Institute, Atlanta
Moffitt Cancer Center, Tampa
Vanderbilt University/Ingram Cancer Center, Nashville
Ohio State University Comprehensive Cancer Center, Columbus
Case Western Reserve University, Cleveland
University of Iowa/Holden Comprehensive Cancer Center, Iowa City
University of Wisconsin Hospital and Clinics, Madison
Billings Clinic Cancer Center, Billings
Mayo Clinic in Arizona, Scottsdale
Johns Hopkins Singapore, Singapore
National Cancer Institute (NCI)
NIH